Sevilito CMC Biotech ApS: Financial statements 2025
CVR: 45431509
Source: annual report 2025, Danish Business Authority
28/02/2025 – 31/12/2025
Sevilito CMC Biotech ApS (CVR 45431509) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 38,271 and a net result of DKK -12,946. The profit margin was -33.8%. Equity in the 2025 report amounted to DKK 27,054. The solvency ratio was 100%.
- Revenue
- DKK 38,271
- Gross Profit
- DKK -12,946
- Profit/Loss
- DKK -12,946
- Equity
- DKK 27,054
- Total Assets
- DKK 27,054
Official annual report
How creditworthy is Sevilito CMC Biotech ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of February 28, 2025, Tore Bengt Søderblom is registered as director of Sevilito CMC Biotech ApS.
As of February 28, 2025, Tore Bengt Søderblom is registered as an owner of Sevilito CMC Biotech ApS with an ownership share of 100%.
Sevilito CMC Biotech ApS was founded on February 28, 2025.
About Sevilito CMC Biotech ApS
Sevilito CMC Biotech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2025. The company is registered under the industry Anden teknisk rådgivning. The management consists of Tore Bengt Søderblom. The company is owned by Tore Bengt Søderblom. The company has 1 employee (2026). In 2025, the company reported revenue of DKK 38,271 and a net result of DKK -12,946. Equity in the 2025 report amounted to DKK 27,054.